bb21217 Shows Encouraging Efficacy, Safety, and CAR T-Cell Expansion

Noopur Raje, MD, director of the multiple myeloma program at Massachusetts General Hospital, discusses the safety and efficacy results of the CRB-402 trial, which evaluated bb21217 in patients with relapsed/refractory multiple myeloma.